Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-10-22
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 9600000 NOK
Award criteria: Lowest price

Technical requirements: Additional contracts with Chiesi Pharma AB after the tender contest LIS 2001b non-parenteral medicines and LIS 2001c parenteral medicines.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for non-parenteral medicines and parenteral medicines ('LIS 2001b non-parenteral medicines and LIS 2001c parenteral medicines — contests).
The contest included the active ingredients that were in accordance with the tender documentation, Annex 3 — the Active Ingredients List. After the contest, tenders were received for the products listed in the annex in this notice, where the Supplier has a marketing licence. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. No other suppliers have a marketing licence for the medicine classified in ATC-codes in the attached spreadsheet.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for non-parenteral medicines and parenteral medicines ('LIS 2001b non-parenteral medicines and LIS 2001c parenteral medicines — contests).
The contest included the active ingredients that were in accordance with the tender documentation, Annex 3 — the Active Ingredients List. After the contest, tenders were received for the products listed in the annex in this notice, where the Supplier has a marketing licence. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. No other Suppliers have a marketing licence for the medicine classified in ATC-codes in the attached spreadsheet. Due to this, LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Chiesi Pharma AB (the Supplier) as an additional contract to LIS 2001b and 2001c, i.e., the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new competition being held for these ingredients.
The health companies that are under the regional health trusts have an option to join the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. LIS has examined the market situation and is of the opinion that it is not possible to hold a new contest, or that a Supplier other than Chiesi Pharma AB can deliver the product in this contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. Cf. the Public Procurement Regulations §13-4, letter b, No 3. LIS requests that those who have objections to this submit feedback before the waiting period expires on 1.11.2019. If no objections are received, a contract will be signed after the waiting period has expired.


Winner: Chiesi Pharma AB
Award value: 9600000